FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $47.61, for a total transaction of $1,839,459.96. Following the completion of the sale, the chief executive officer now owns 3,029,887 shares of the company’s stock, valued at approximately $144,252,920.07. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
FibroGen Inc (FGEN) opened at $48.00 on Thursday. The company has a market cap of $3,950.00, a price-to-earnings ratio of -23.65 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. FibroGen Inc has a 12-month low of $21.05 and a 12-month high of $60.15.
Several analysts recently commented on FGEN shares. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Stifel Nicolaus reiterated a “buy” rating and issued a $80.00 price target on shares of FibroGen in a research report on Thursday, September 14th. Mizuho started coverage on shares of FibroGen in a research report on Wednesday, October 4th. They issued a “neutral” rating and a $61.00 price target for the company. Finally, ValuEngine downgraded shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $65.67.
Institutional investors have recently made changes to their positions in the business. Quantbot Technologies LP purchased a new position in FibroGen during the 2nd quarter worth $128,000. Ameritas Investment Partners Inc. raised its position in FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 696 shares during the last quarter. SG Americas Securities LLC raised its position in FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Amalgamated Bank purchased a new position in FibroGen during the 2nd quarter worth $237,000. Finally, Oppenheimer Asset Management Inc. raised its position in FibroGen by 112.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after buying an additional 2,336 shares during the last quarter. Institutional investors own 57.23% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/insider-selling-fibrogen-inc-fgen-ceo-sells-1839459-96-in-stock.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.